NFCR Writer David Perry, Author at NFCR - Page 2 of 6

NFCR Writer David Perry

Liver Cancer: A Primer

With October being recognized as Liver Cancer Awareness Month, the National Foundation for Cancer Research (NFCR) presents to you a quick overview of the disease—and too insight into the importance of early detection and recent advances to that end. According to a July 2018 report from the U.S. Centers for…...

Read more

Breast Exams: At Home or Clinic?

There is a grim reality to both cancer research and funding: Each, to an enormous degree, is directed at early detection, not when metastasis has already taken place. Like most diseases, cancer is, in fact, fairly curable at its earliest stages. However, once a tumor begins to spread, mortality rates…...

Read more

Protein Identified in Breast Cancer Metastasis

Researchers from the University of Liverpool have found an explanation for how breast cancer spreads to the lungs, which could potentially hold the key to preventing the progression of the disease. Led by Dr. Ainhoa Mielgo, the research team conducted a study to gain a better understanding of how breast…...

Read more

Artemisinin Therapies: Connecting the Dots

You wouldn’t think it, but the science cannot be denied: One of the newest and most promising drug candidates for cancer was actually developed all the way back in 1972. For malaria. “There were some hints in the literature, but we were totally ignorant,” admits Curt Civin, M.D., whose work…...

Read more

The Lucy Fund: Words of a Mother

Lucy Elicker Stanovick, an English professor, writer, wife and mother of two, received the news that she had Stage IV metastatic breast cancer in April 2008. Although active, health conscious and just 42 years old, she was faced suddenly with her mortality: Stage IV metastatic breast cancer cannot be cured,…...

Read more

Szent-Györgyi Prize Winner Profile Series: Peter Vogt: The Game Changer

The term “game changer” didn’t come into English usage until 1993, and since then it has been driven into the ground from overuse. But when applied to Dr. Peter Vogt, it is more than just hyperbole or overzealous marketing. When you are talking about the person that identified src, the…...

Read more

September is Blood Cancer Awareness Month

To bring attention to leukemia and lymphoma, Congress in 2010 designated September as Blood Cancer Awareness Month. These diseases are diagnosed in 14,000 people monthly within the United States. But with advances in treatment and technologies yielding earlier and earlier detection, the overall five-year relative survival rate for leukemia has…...

Read more

The Development of Better Ovarian Cancer Biomarkers

“The trouble with ultrasound is that it doesn’t detect many ovarian cancers early,” says Robert Bast, M.D., Vice President for Translational Research at MD Andersen Cancer Center in Houston. Moreover, “Ultrasound doesn’t see really small cancers in the ovary.”...

Read more

Pediatric Cancer Drug Has 93 Percent Effectiveness

A new cancer drug, larotrectinib, has in a very early clinical trial been shown to have a 93% (14/15) effectiveness rate for pediatric cancers; that is to say, for not just one cancer, but many. Hailed by the U.S. Food and Drug Administration as a “breakthrough therapy,” larotrectinib targets a…...

Read more

Cloud Atlas

It’s called “the cloud,” but it is not the fluffy white thingees drifting overhead. It promises to revolutionize cancer care. By, of all things, sharing data. “In cancer, only about 4% of patients go on a clinical trial, but that data is not ever really leveraged. The FDA (U.S. Food…...

Read more